The Efficacy of Moxibustion for Breast Cancer Patients with Chemotherapy-Induced Myelosuppression during Adjuvant Chemotherapy: A Randomized Controlled Study.
The Efficacy of Moxibustion for Breast Cancer Patients with Chemotherapy-Induced Myelosuppression during Adjuvant Chemotherapy: A Randomized Controlled Study.
复制标题
DOI：
10.1155/2021/1347342
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Xue X
中科院分区：
文献类型：
--
作者：
Ji Y;Li S;Zhang X;Li Q;Lu Q;Chen W;Liu Y;Sheng J;Liang H;Jiang K;Li M;Sha S;Wu H;Huang Y;Xue X
本随机对照临床试验旨在探讨艾灸治疗乳腺癌患者辅助化疗期间化疗所致骨髓抑制（CIM）的临床疗效。 将手术切除的乳腺癌患者随机分为艾灸组（MOX; n = 48）和对照组（CON; n = 44）。两组均给予常规辅助化疗（每21天1次，4-8个周期）及重组人粒细胞集落刺激因子支持治疗，并在此基础上加用艾灸治疗（每周期化疗后每日1次）。主要终点包括根据白色血细胞（WBC）和中性粒细胞绝对计数（ANC）的骨髓抑制等级以及骨髓抑制相关严重不良事件（SAE）的发生率。其他指标包括治疗依从性、不良事件（AE）和生存率。 MOX组WBC计数普遍高于CON组（P=0.008），第7疗程时明显高于CON组（P= 0.006），而ANC 1级下降明显低于CON组（P=0.006）。这些影响在接受蒽环类-紫杉烷联合方案的患者中尤其显著。此外，MOX的发热性中性粒细胞减少症少于CON（P=0.051）。MOX组3-4级骨髓抑制发生率较低（P < 0.05）。MOX组2-3级严重恶心、各种疼痛、眩晕等不良事件发生率较低（P < 0.05）。两组生存率无显著性差异（P > 0.05）。 莫西沙星对乳腺癌患者辅助化疗期间的CIM治疗有效，特别是对于接受高剂量，长期和联合化疗方案的患者。莫西沙星可降低骨髓抑制相关SAE的发生率，提高乳腺癌化疗的依从性和安全性。
The randomized controlled clinical trial aims to investigate the clinical efficacy of moxibustion for breast cancer patients with chemotherapy-induced myelosuppression (CIM) during adjuvant chemotherapy. Surgically resected breast cancer patients were randomly divided into the moxibustion group (MOX; n = 48) and control group (CON; n = 44). Routine adjuvant chemotherapy (every 21 days, 4–8 cycles) and supportive recombinant human granulocyte colony-stimulating factor were given to both groups, while MOX received an additional moxibustion treatment (once daily after each cycle of chemotherapy). Primary endpoints included the grade of myelosuppression in terms of white blood cell (WBC) and absolute neutrophil count (ANC) and the incidence of myelosuppression-related serious adverse events (SAEs). Other measures included treatment compliance, adverse events (AEs), and survival. WBC counts were generally higher in MOX and were dramatically higher than those in CON at the 7th course of chemotherapy (P=0.008), while grade 1 ANC reduction was dramatically lower than that in CON at the 7thcourse of chemotherapy (P=0.006). These effects were particularly significant in patients receiving anthracycline-taxane combination regimens. Moreover, MOX had fewer febrile neutropenia than CON (P=0.051). MOX demonstrated a lower incidence of grade 3–4 myelosuppression (P < 0.05). AEs including grade 2–3 severe nausea, various kinds of pains, and vertigo occurred less frequently in MOX (P < 0.05). No difference in survival was observed between the two groups (P > 0.05). Moxibustion is effective for treating CIM in breast cancer patients during adjuvant chemotherapy, especially for patients receiving high-dose, long-term, and combined chemotherapy regimens. Moxibustion can reduce the incidence of myelosuppression-related SAE and improve the compliance and safety of chemotherapy in breast cancer.
登录
查看更多内容
影响因子：
10.3
作者：
Hershman, Dawn;Neugut, Alfred I.;Grann, Victor R.
通讯作者：
Grann, Victor R.
影响因子：
2.5
作者：
Ji Y;Li S;Zhang X;Liu Y;Lu Q;Li Q;Chen W;Sheng J;Jiang K;Liang H;Sha S;Li M;Chen Z;Zheng P;Wang M;Feng Y;Wang L;Wu H;Liu H;Huang Y;Yin Z;Xue X
通讯作者：
Xue X
影响因子：
158.5
作者：
ANTMAN, KS;GRIFFIN, JD;SCHNIPPER, LE
通讯作者：
SCHNIPPER, LE
DOI：
10.6004/jnccn.2016.0093
发表时间：
2016-07-01
影响因子：
13.4
作者：
Baden, Lindsey Robert;Swaminathan, Sankar;Smith, Courtney
通讯作者：
Smith, Courtney
影响因子：
45.3
作者：
Smith, Thomas J.;Bohlke, Kari;Armitage, James O.
通讯作者：
Armitage, James O.